Select studies of biologic prognostic markers in peripheral T-cell lymphoma, not-otherwise specified.
| Prognostic Marker . | Study . | Outcome . | Comment . |
|---|---|---|---|
| * TIA-1 and Granzyme B | |||
| Abbreviations: EBV, Epstein Barr Virus; EBER, EBV-encoded small nonpolyadenylated RNAs; GELA, Groupe d’Etudes des Lymphomes de l’Adulte; NS, not significant; ITLP, International Peripheral T-cell Lymphoma Project; NCI, National Cancer Institute; MVA, multivariate analysis | |||
| EBV (EBER) | GELA36 | Unfavorable | Only > 60 y MVA marker NS |
| Italy39 | Unfavorable | MVA marker NS | |
| ITLP37 | Unfavorable | < 60 y MVA marker NS | |
| Ki-67 ≥ 80% | Italy39 | Unfavorable | MVA marker significant |
| Cytotoxic granule expression* | Japan38 | Unfavorable | MVA marker significant |
| T-helper receptor profile | |||
| ST2(L) or CCR5 or CXCR3 | Japan34 | Favorable | None of these markers |
| CCR3 | Japan35 | Favorable | tested in MVA |
| CCR4 | Japan35 | Unfavorable | |
| % transformed cells > 70% | ITLP37 | Unfavorable | MVA marker significant |
| Prognostic gene signatures | |||
| Proliferation signature | Spain/NCI42 | Unfavorable | MVA proliferation signature significant but not Ki-67 |
| NFκB signature | Spain43 | Favorable | MVA NFκB signature significant |
| Prognostic Marker . | Study . | Outcome . | Comment . |
|---|---|---|---|
| * TIA-1 and Granzyme B | |||
| Abbreviations: EBV, Epstein Barr Virus; EBER, EBV-encoded small nonpolyadenylated RNAs; GELA, Groupe d’Etudes des Lymphomes de l’Adulte; NS, not significant; ITLP, International Peripheral T-cell Lymphoma Project; NCI, National Cancer Institute; MVA, multivariate analysis | |||
| EBV (EBER) | GELA36 | Unfavorable | Only > 60 y MVA marker NS |
| Italy39 | Unfavorable | MVA marker NS | |
| ITLP37 | Unfavorable | < 60 y MVA marker NS | |
| Ki-67 ≥ 80% | Italy39 | Unfavorable | MVA marker significant |
| Cytotoxic granule expression* | Japan38 | Unfavorable | MVA marker significant |
| T-helper receptor profile | |||
| ST2(L) or CCR5 or CXCR3 | Japan34 | Favorable | None of these markers |
| CCR3 | Japan35 | Favorable | tested in MVA |
| CCR4 | Japan35 | Unfavorable | |
| % transformed cells > 70% | ITLP37 | Unfavorable | MVA marker significant |
| Prognostic gene signatures | |||
| Proliferation signature | Spain/NCI42 | Unfavorable | MVA proliferation signature significant but not Ki-67 |
| NFκB signature | Spain43 | Favorable | MVA NFκB signature significant |